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Thrombus formation in the thoracic and abdominal aorta without evidence of arteriosclerotic disease is very uncommon.
We present a case of a 50-year-old woman with a mural thrombus of the upper abdominal aorta associated with a
combination of two mutations predisposing for thrombophilia. The genetic analysis showed a homozygous mutation of
plasminogen activator inhibitor type 1 (PAI-1)-675 (4G) and a heterozygous mutation of GP Ia 807C/T. To our
knowledge, this is the first report of the combination of both mutations occurring in a patient with isolated thrombus
formation of the aorta. (J Vasc Surg 2002;36:632-4.)
Mural aortic thrombi have been recognized more fre-
quently in the past years because of improved diagnostic
instruments.1 Thrombus formation in the thoracic and
abdominal aorta is primarily the result of underlying arte-
riosclerotic or aneurysmatic disease, and can lead to major
morbidity and mortality. Visceral and peripheral embolism
may lead to surgical emergencies and mandate rapid inter-
vention. However, aortic mural thrombus formation in an
aorta without morphologic alterations has been reported
rarely.2 After exclusion of common causes, we report an
unusual case of aortic mural thrombus occurring in a rela-
tively young patient with an inherited thrombophilia.
CASE REPORT
An otherwise healthy 50-year-old woman presented with a
history of 24 hours of progressive periumbilical and lower abdom-
inal pain. There were no signs of distal limb ischemia, such as pain
and pallor. Further, the patient had palpable pulses. She had no
personal and no family history of arteriosclerotic or thrombotic
disease and was not taking any medication. There were no risk
factors for arteriosclerosis or thrombosis: She is a nonsmoker, has
normal cholesterol and glucose levels, and is not taking estrogens.
Abdominal computed tomography revealed a localized supra-
renal mural thrombus located ventrally in the visceral aorta (Fig).
The celiac trunk was completely occluded, and the superior mes-
enteric artery was partially occluded. In addition, free intraperito-
neal fluid, splenic infarcts, and a myoma (diameter, 7 cm) of the
uterus were observed. Angiography was not performed, as there
was no clinical evidence of other sites of thromboembolism except
for the intestine, the kidney, and the spleen as viewed in the
computed tomography.
The patient underwent emergency transabdominal thrombec-
tomy of the visceral aorta. After performing a left rotation of the
abdominal organs, the aorta was clamped 3 cm cranial to the celiac
trunk and just proximal to the renal arteries. The thrombus was
removed after longitudinal arteriotomy of the aorta. The surface of
the aorta beneath the thrombus was macroscopically normal with-
out any signs of arteriosclerotic or other lesions. The thromboem-
bolic material in the superior mesenteric artery and celiac trunk
were removed with use of a Fogarty maneuver.
On histopathologic examination, the thrombus consisted
mainly of fresh fibrin. The attached vessel wall was without any
histopathologic abnormalities, eg, inflammation, atherosclerosis,
or dissection. Approximately 30 cm of necrotic ileum was resected.
A repeat procedure to assess the bowel viability was performed 24
hours later and showed no residual necrotic intestine. A computed
tomography with contrast of the abdomen and thorax performed
14 days postoperatively revealed no source of thrombus, yet again
demonstrated the splenic infarcts. In addition, the evaluation
showed small renal infarcts. Echocardiography revealed no abnor-
mality, making a cardiac source unlikely.
Systemic heparin therapy was initiated intraoperatively and
continued until therapeutic anticoagulant levels were achieved
with phenprocoumon. The patient was asymptomatic at follow-up
6 months after intervention.
An extensive coagulation work-up revealed an increased level
of plasminogen activator inhibitor type 1 (PAI-1) in the plasma.
The genetic analysis showed a homozygous mutation of PAI-1-
675(4G) and a heterozygous mutation of GP Ia 807C/T. The
classic, more common, disorders associated with arterial or venous
thromboembolic diseases such as hyperhomocysteinemia, anti-
thrombin-III deficiency, activated protein-C resistance, lupus an-
ticoagulant, anticardiolipin antibodies, anti-2-glycoprotein-1 an-
tibodies, prothrombin mutation, and dysfibrinogenemia were
ruled out. Of the tests performed, those for lupus anticoagulant,
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protein C, and protein S are altered by oral anticoagulation,
whereas antithrombin III is decreased by heparin therapy. The
results of the other tests are not influenced by anticoagulation, as
they are based mainly on molecular biology and performed by
extraction of deoxyribonucleic acid (DNA) from leukocytes.
In addition, an inflammatory cause was ruled out by normal
blood sedimentation rate, baseline C-reactive protein level, ab-
sence of antineutrophil cytoplasmatic antibodies, normal serum
protein electrophoresis, absence of fragmentocytosis, normal
platelet count, normal hemogram, and no histologic pathology in
the few fragments attached to the excised thrombus. Tissue factor
pathway inhibitor (TFPI) and human platelet antigen (HPA)
genotype were wildtype.
DISCUSSION
Mural aortic thrombus formation without signs of ar-
teriosclerosis or aortic aneurysm is unusual. The largest
series were presented by Hahn and coworkers,2 with six
cases over a period of 3.5 years of which one patient had a
positive Ham test and in another a positive anticardiolipin
immunoglobulin (Ig)G was found.
Celiac axis compression syndrome was clinically ruled
out because the patient did not have chronic abdominal
pain. Furthermore, thrombus formation in the aorta and
superior mesenteric artery is very atypical in celiac axis
compression syndrome.
In the case we described, we found two polymor-
phisms: homozygous PAI-1-675(4G) and heterozygous
GP Ia 807C/T genotypes. Other disease entities such as
paroxysmal nocturnal anemia and most recently described
thrombophilic autoantibodies against annexin V, factor II,
and protein S were not addressed. However, there was little
evidence for presence of these disorders with a patient
observation time of more than 15 months.
The main function of PAI-1 is inhibition of tissue
plasmin activator (tPA). In healthy individuals the interac-
tion of PAI-1 and tPA inhibits the development of systemic
fibrinolysis and systemic bleeding while permitting local
clot lysis. Mutation of the PAI-1 gene is weakly associated
with elevated plasma levels of PAI-1, leading to impaired
fibrinolysis. Mutations of PAI-1 have been related to coro-
nary artery disease, usually in association with other cardio-
vascular risk factors.3-5 A metaanalysis revealed a weak
significant effect of PAI-1 genotype on myocardial infarc-
tion.6 GP Ia polymorphism 807C/T increases platelet re-
ceptor density of the collagen receptor glycoprotein Ia/
IIa.7 An association of this polymorphism and the risk of
myocardial infarction with an odds ratio of 3.3 has been
demonstrated.8 Because GP 1a polymorphism results in an
increased binding of platelets to collagen, which is exposed
during vascular damage, it can be assumed that there will be
a greater influence on arterial than on venous thromboem-
bolism. The genotype frequency in healthy Caucasian con-
trols of the homozygous 4G/4G polymorphisms of PAI-
1-675 is 26% and of the heterozygous GP Ia 807C/T is
47%.4,8 At present, no data exist about the frequency of the
combination of these polymorphisms. Mutations of PAI-1
and GP Ia alone are associated with weak increased risk of
arterial thrombotic disease. The frequencies for the com-
bined genetic states as seen in our case, can be calculated,
and amount to approximately 2.9%. Thus, it can be con-
cluded that the association of these two mutations will
significantly increase the hypercoagulable risk. Case-con-
trol studies are needed to show the incidence and signifi-
cance of this combination in patients with arterial throm-
botic disease. In addition, the combination of these two
mutations could be responsible for additional arterial
thromboembolic disorders with unknown etiology.
On the basis of the relatively young age of the patient
and the severity of the arterial thrombotic event, we advo-
cated life-long oral anticoagulation. Furthermore, the ge-
netic defects found will constitute a permanent risk for
future thromboembolic events and outbalance the risk for
major bleeding due to long-term oral anticoagulation.
In conclusion, in a rare event such as mural aortic
thrombus formation in a relatively young patient, the clas-
sic coagulation disorders have to be excluded first. If these
tests are negative, further investigation for more unusual
coagulation disorders such as GP Ia and PAI-1 polymor-
phisms; TFPI; HPA; and autoantibodies against annexin V,
factor II, and protein S should be considered.
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